Use ctDNA as an objective measure to support earlier efficacy readouts for clinical trials. MRD tests provide molecular-level detection of residual disease, predicting patients most likely to experience disease recurrence or progression. Integrating MRD testing timepoints into trial designs allows for the inclusion of meaningful surrogate endpoints, such as ctDNA clearance, to support more robust and timely efficacy evaluations.
